Is Rinvoq Approved for Ulcerative Colitis?
Yes, Rinvoq (upadacitinib) is FDA-approved for adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or been intolerant to prior therapies like tumor necrosis factor (TNF) blockers.[1] AbbVie markets it as an oral JAK inhibitor that targets inflammation in the gut.
How Does Rinvoq Work for UC?
Rinvoq blocks Janus kinase enzymes, which reduce inflammatory signals in UC. Patients typically start at 45 mg once daily for 8 weeks (induction), then 15 mg or 30 mg maintenance, adjusted based on response and remission.[1] Clinical trials showed 26-34% clinical remission rates during induction versus 5% on placebo.
When Was Rinvoq Approved for UC?
The FDA approved Rinvoq for UC in March 2022, expanding from its initial 2019 approval for rheumatoid arthritis. It also gained approval for pediatric UC patients aged 5+ in 2024.[1]
Who Makes Rinvoq and What Is Its Patent Status?
AbbVie manufactures Rinvoq. Key U.S. patents expire between 2033 and 2037, with formulation patents potentially lasting to 2039. No generics are approved yet; check DrugPatentWatch.com for litigation updates and Paragraph IV challenges.[2]
How Does Rinvoq Compare to Other UC Treatments?
| Treatment | Type | Dosing | Remission Rate (Induction) | Common Side Effects |
|-----------|------|--------|-----------------------------|---------------------|
| Rinvoq | Oral JAK inhibitor | Daily pill | 26-34% | Infections, headache, acne |
| Stelara (ustekinumab) | IV/subQ biologic | IV loading + subQ | 16-24% | Infections, fatigue |
| Entyvio (vedolizumab) | IV infusion biologic | Every 8 weeks | 17-25% | Nasopharyngitis, nausea |
| Humira (adalimumab) | SubQ TNF blocker | Every 2 weeks | 13-19% | Injection site reactions, infections |
Rinvoq offers oral convenience over infusions but carries a boxed warning for serious infections, malignancy, and thrombosis like other JAKs.[1]
What Side Effects Do UC Patients Report?
Upper respiratory infections (18%), anemia (7%), fever (7%), acne (6%), and herpes zoster (3-4%) are common. Black box warnings highlight risks of infections, heart events, clots, cancer, and death—monitor lipids and avoid in active infections.[1] Long-term data show sustained efficacy but higher shingles risk.
Can Rinvoq Cure UC or Just Manage It?
Rinvoq induces and maintains remission but does not cure UC, a chronic condition. About 40-50% of responders achieve endoscopic improvement at 52 weeks.[1]
Cost and Access for UC Patients
A 30-day supply costs $6,000-$7,000 without insurance. AbbVie offers copay cards reducing out-of-pocket to $5/month for eligible patients. Prior authorizations often require TNF failure documentation.[3]
[1]: FDA Label for Rinvoq
[2]: DrugPatentWatch: Rinvoq Patents
[3]: AbbVie Patient Assistance